Researchers from Okayama University have developed a method to treat the congenital heart defect known as hypoplastic left heart syndrome [HLHS] by utilizing a specialized cardiac stem cell. In a Phase I clinical trial conducted on children suffering from HLHS, the scientists concluded that, because the young stem cells in children are more abundant and self-renewing than those in adults, intracoronary injection of stem cells is a safe and feasible approach to treating the condition.
Topics: Heart Valve, Phase III, Heart, Heart Failure, Pediatric Congenital Heart Disease, clinical trials, Debilitating Diseases, Stemcells, hypoplastic left heart syndrome, Heart Attack, autologousstemcells, heart disease, stemsaveblog
According to new research from the National Yang-Ming University, mesenchymal stem cells [MSCs] hold the ability to limit atherosclerotic plaque formation, thereby preventing the onset of harmful endothelial lesions. The research team, led by Shih-Chieh Hung, transplanted MSCs into animal models with atherosclerosis and observed significant reduction in plaque formation. They also saw an increase in blood vessel dilation, which prevents further plaque development, indicating good endothelial health.
Researchers led by Eduardo Marbón of the Cedars-Sinai Heart Institute have developed a method to prolong the lives of patients with Duchenne Muscular Dystrophy [DMD] through the infusion of cardiac stem cells. The stem cells reverse the loss of cardiac muscle caused by the genetic disease, preventing heart failure that would otherwise limit a patient’s life expectancy to age 25.
A team of bioengineers from Tel Aviv University is currently developing a scaffold to help regenerate heart muscle through the use of autologous stem cells. The scientists, led by Dr. Tal Dvir, aim to replace damaged cardiac tissue in heart attack patients by creating a scaffold out of collagen and gold nanoparticles, and then infusing it with the patient’s own stem cells to stimulate the rejuvenation of cardiomyocytes.
In a recent clinical study conducted in Beijing, researchers are testing a treatment for patients suffering from systemic lupus erythematosus by administering autologous [the patient’s own] mesenchymal stem cells. The researchers aim to capitalize on the unique abilities of MSCs to not only differentiate into a multitude of different cell types, but to reduce the autoimmune attack in patients affected by lupus as well.
As reported on the front page of the New York Times Science section, clinical applications of stem cell based therapies are accelerating at a rate that will revolutionize the medical field in a matter of years. In the United States alone, there are currently over 4000 therapies in clinical trials for the treatment of heart disease, blindness, spinal cord injuries, diabetes, H.I.V., and other diseases, injuries, and traumas.
Topics: Muscular Dystrophy, ALS, Parkinson's, Phase III, multiple sclerosis, Heart, Joints, Alzheimer's, burn injuries, Diabetes, Acute Myocardial Infarction, Brain, Heart Failure, clinical trials, Bone, Debilitating Diseases, Phase II, Arthritis, Stemcells, Teeth, autologousstemcells, cartilage, Amyotrophic lateral sclerosis, Brain Tumors, Blindness, stemsaveblog
A team of scientists from the Harvard Stem Cell Institute and the Boston Children’s Hospital have developed a method to increase the survival rate, and therefore the effectiveness, of transplanted mesenchymal stem cells [MSCs]. In an animal model, Dr. Juan Melero-Martin and his team of researchers co-transplanted MSCs with blood vessel-forming cells, enabling the stem cells to survive longer in a patient to reach their full regenerative potential.
A team of scientists from the Wyss Institute, Boston Children’s Hospital, and Harvard’s Medical School, Stem Cell Institute, and School of Engineering has created a model to study and develop treatments for the genetic heart disorder Barth Syndrome by utilizing a patient’s own stem cells in conjunction with an organ-on-a-chip. The chip was outfitted with proteins to mimic the cellular environment of the heart, causing the patient’s stem cells to differentiate into diseased heart tissue. The tissue was then studied to not only determine the cause of the disease, but to treat the diseased tissue as well.
A team of researchers led by Dr. Gordana Vunjak-Novakovic [a member of StemSave’s Scientific Advisory Council has engineered a scaffold to facilitate the regeneration of heart muscle through the use of adult stem cells. In an animal model, Vunjak-Novakovic and her team created a scaffold using biodegradable chitosan and carbon nanofibers, infusing it with stem cells to provoke the regeneration of beating cardiomyocytes.
Research teams from Cedars-Sinai Heart Institute and the Minneapolis Heart Institute with funding from CIRM [California Institute for Regenerative Medicine] are moving to Phase 2 Clinical Trials for a treatment that utilizes cardiac stem cells to repair severe heart damage. The treatment development was led by Eduardo Marbán, a director at the Cedars-Sinai Heart Institute and founder of Capricor. This groundbreaking treatment involves the injection of stem cells into the coronary artery, which then migrate to the heart and promote the regrowth of healthy heart muscle.
Topics: Heart Valve, Phase III, Heart, Acute Myocardial Infarction, Heart Failure, clinical trials, Debilitating Diseases, Phase II, Stemcells, Heart Attack, autologousstemcells, heart disease, stemsaveblog